The recent event demonstrated the company’s successful strategy in targeting industry verticals, smoothing the way for virtual agents and navigating the business challenge of CX.
Gilead Sciences, Inc. today announced The New England Journal of Medicine (NEJM) published the full results from the company's pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for ...
Deal Could End Israel-Hezbollah Conflict That Has Lasted Over a Year Lebanon’s caretaker cabinet is expected to meet to formally approve the deal, in which it would play an essential role. Maps ...